A recent study on preclinical models suggests that administering psilocybin, the psychoactive compound in certain hallucinogenic mushrooms, before chemotherapy might help prevent nerve damage. This could potentially reduce common side effects like pain, numbness, and sensitivity to cold, which often occur due to chemotherapy-induced peripheral neuropathy. Peripheral neuropathy involves damage to the peripheral nerves, which can cause long-lasting discomfort and is difficult to treat effectively. Researchers from the MD Anderson Cancer Center at the University of Texas (UT MDAnderson) are exploring a strategy to prevent nerve damage using psilocybin. Moran Amit, an associate professor of head and neck surgery at UT MDAnderson, co-led the study and emphasized the need for treatments that can prevent nerve damage without interfering with the effectiveness of chemotherapy. The findings, published in the journal Science, suggest that psilocybin may protect nerves before damage occurs, rather than just treating symptoms after they develop. Psilocybin is being increasingly studied for its potential in treating neuropsychiatric and neurological conditions. It is known to activate serotonin 5-HT2A receptors, which are linked to neural plasticity—the brain's ability to reorganize and form new connections. Amit's team hypothesized that this plasticity might help prevent nerve damage. Using mouse models, they tested how psilocybin affects nerve cells and whether it could prevent peripheral neuropathy caused by chemotherapy. The study found that psilocybin protects the peripheral nervous system through the 5-HT2A receptors. In mice, two doses of psilocybin given before chemotherapy prevented cold hypersensitivity, protected sensory nerve endings, and preserved the ability to feel touch, without reducing the effectiveness of chemotherapy against tumors. These protective effects remained even after multiple chemotherapy cycles. In another experiment, blocking the 5-HT2A pathway reversed these benefits, while a non-hallucinogenic compound that activates the same receptors provided similar protection. The study also found that psilocybin helped maintain mitochondrial function in nerve cells, which is crucial for providing energy and preventing damage from chemotherapy. According to Amit, these findings extend the known uses of psychedelics, which have traditionally been studied for conditions like depression and PTSD. This study is the first to show significant effectiveness in preventing pain rather than treating it. The results will now be used to design a phase 2 clinical trial to evaluate psilocybin's effects in cancer patients undergoing chemotherapy. However, the preventive benefits observed in the study have not yet been confirmed in human patients.